Loading…
BALAXI PHARMACEUTICALS (BALAXI)₹22.66+1.43%Pharmaceuticals
In the Jun 2026 quarter (consolidated), BALAXI PHARMACEUTICALS reported sales of ₹80.58 Cr, up 14.1% from Jun 2025, and net profit of ₹1.31 Cr, up 336.7% year on year. For the year to Mar 2026, sales were ₹270 Cr and net profit ₹1.01 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 54.66 | 60.75 | 59.77 | 65.52 | 77.30 | 73.21 | 76.21 | 70.61 | 56.12 | 72.46 | 70.65 | 80.58 |
| Expenses | 43.93 | 47.13 | 46.39 | 55.54 | 66.75 | 69.24 | 63.69 | 66.53 | 55.00 | 69.42 | 70.62 | 76.01 |
| Operating Profit | 10.78 | 13.68 | 13.51 | 10.10 | 10.62 | 4.00 | 12.57 | 4.17 | 1.17 | 3.10 | 0.13 | 4.67 |
| OPM % | 19.7% | 22.5% | 22.5% | 15.4% | 13.7% | 5.5% | 16.4% | 5.9% | 2.1% | 4.3% | 0.2% | 5.8% |
| Other Income | 5.94 | 1.52 | −0.71 | −1.86 | −4.12 | 3.95 | −1.70 | −1.79 | 1.60 | 0.11 | 2.93 | −1.00 |
| Interest | 0.36 | 0.40 | 0.60 | 0.36 | 0.44 | 1.37 | 0.73 | 1.00 | 0.88 | 1.01 | 0.98 | 0.72 |
| Depreciation | 0.67 | 0.49 | 0.68 | 0.50 | 0.47 | 0.49 | 0.47 | 0.47 | 0.49 | 0.57 | 0.66 | 0.86 |
| Profit before tax | 15.62 | 14.23 | 11.45 | 7.35 | 5.55 | 6.05 | 9.62 | 0.90 | 1.37 | 1.60 | 1.39 | 2.08 |
| Tax % | 8.0% | 4.8% | 4.9% | 12.1% | 17.5% | 11.8% | 10.6% | 67.1% | 84.1% | 80.8% | 56.5% | 38.4% |
| Exceptional items | 4.99 | 1.99 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 14.46 | 13.60 | 10.94 | 6.50 | 4.60 | 5.37 | 8.65 | 0.30 | 0.22 | 0.32 | 0.62 | 1.31 |
| EPS (Rs) | 2.81 | 2.64 | 2.00 | 1.16 | 0.82 | 0.96 | 1.56 | 0.04 | 0.03 | 0.05 | 0.10 | 0.23 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.99 | 45.97 | 231 | 279 | 336 | 241 | 293 | 270 | 280 |
| Expenses | 12.01 | 36.97 | 189 | 229 | 279 | 197 | 260 | 262 | 271 |
| Operating Profit | 2.01 | 8.02 | 43.09 | 51.08 | 57.15 | 45.12 | 32.06 | 9.02 | 9.07 |
| OPM % | 11.0% | 18.0% | 18.0% | 18.0% | 17.0% | 18.0% | 11.0% | 3.2% | 3.2% |
| Other Income | 1.01 | 1.01 | 2.01 | 5.01 | 3.01 | −38.06 | 2.01 | 3.01 | 3.64 |
| Interest | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 2.99 | 3.98 | 3.98 | 3.59 |
| Depreciation | 0.00 | 0.00 | 0.00 | 1.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.58 |
| Profit before tax | 1.99 | 8.97 | 43.86 | 54.84 | 56.80 | 1.99 | 28.89 | 4.99 | 6.44 |
| Tax % | 19.1% | 31.1% | 14.1% | 13.1% | 19.1% | 219.1% | 13.0% | 73.1% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.91 | 0.00 | 0.00 | 0.00 |
| Net Profit | 2.01 | 6.01 | 38.09 | 48.09 | 46.09 | −2.01 | 25.03 | 1.01 | 2.47 |
| EPS (Rs) | 1.29 | 1.21 | 7.61 | 9.51 | 9.01 | −0.43 | 4.53 | 0.25 | 0.41 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.01 | 10.00 | 9.99 | 10.00 | 10.00 | 11.02 | 11.02 | 11.03 |
| Reserves | 0.00 | 17.96 | 54.84 | 103 | 173 | 190 | 221 | 238 |
| Borrowings | 0.00 | 0.00 | 3.99 | 3.99 | 12.99 | 18.98 | 52.99 | 58.05 |
| Other Liabilities | 3.00 | 8.03 | 31.15 | 60.29 | 43.21 | 38.19 | 25.13 | 30.14 |
| Total Liabilities | 6.01 | 35.99 | 99.97 | 176 | 240 | 258 | 310 | 337 |
| Fixed Assets | 0.00 | 0.00 | 2.01 | 29.03 | 41.03 | 41.03 | 40.99 | 82.05 |
| CWIP | 0.00 | 0.00 | 0.00 | 1.01 | 3.01 | 2.01 | 22.07 | 0.00 |
| Investments | 0.00 | 0.00 | 3.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 6.01 | 35.99 | 93.95 | 147 | 195 | 215 | 247 | 255 |
| Inventories | 0.00 | 0.99 | 13.99 | 98.95 | 105 | 81.87 | 77.89 | 82.93 |
| Trade receivables | 4.99 | 29.93 | 76.84 | 27.93 | 51.89 | 55.85 | 111 | 136 |
| Cash & equivalents | 0.00 | 3.98 | 1.99 | 6.98 | 27.88 | 61.81 | 38.85 | 14.93 |
| Total Assets | 6.01 | 35.99 | 99.97 | 176 | 240 | 258 | 310 | 337 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −2.01 | −14.05 | 0.00 | 34.15 | 6.03 | 5.02 | −35.14 | −4.02 |
| Cash from investing activity | 0.00 | 0.00 | −6.02 | −28.10 | −11.03 | −1.01 | −22.06 | −21.06 |
| Cash from financing activity | 0.00 | 17.97 | 3.99 | 0.00 | 25.94 | 29.97 | 33.92 | 0.00 |
| Net cash flow | −2.01 | 4.02 | −2.01 | 6.02 | 21.07 | 34.15 | −23.10 | −25.09 |
| Capex | 0.00 | 0.17 | 2.55 | 26.72 | 14.94 | 1.56 | 1.99 | 42.78 |
| Free cash flow | −2.01 | −14.05 | −3.01 | 7.02 | −9.03 | 4.01 | −57.15 | −25.07 |
| CFO / OP % | −97.0% | −161.0% | 6.0% | 78.1% | 32.0% | 26.0% | −98.0% | 3.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 147 | 238 | 121 | 36 | 57 | 84 | 138 | 184 |
| Inventory days | — | 9 | 29 | 184 | 189 | 233 | 173 | 202 |
| Days payable | — | 64 | 53 | 92 | 62 | 82 | 36 | 51 |
| Cash conversion cycle | 148 | 184 | 98 | 130 | 185 | 236 | 276 | 336 |
| Working capital days | 82 | 181 | 91 | 92 | 122 | 142 | 186 | 236 |
| ROCE % | — | 57.0% | 93.1% | 60.0% | 37.0% | 21.0% | 13.0% | 3.0% |
For the Jun 2026 quarter, BALAXI PHARMACEUTICALS reported sales of ₹80.58 Cr, up 14.1% year on year and net profit of ₹1.31 Cr, up 336.7% year on year. The operating margin was 5.8%.
BALAXI PHARMACEUTICALS' sales for the year to Mar 2026 were ₹270 Cr; over the last twelve months they were ₹280 Cr.
Net profit for the year to Mar 2026 was ₹1.01 Cr, and ₹2.47 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.41.
BALAXI PHARMACEUTICALS reported borrowings of ₹58.05 Cr at Mar 2026, against cash and equivalents of ₹14.93 Cr.
Cash from operations was −₹4.02 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹25.07 Cr.